Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · Real-Time Price · USD
1.490
-0.060 (-3.87%)
Mar 25, 2025, 4:00 PM EST - Market closed
Citius Pharmaceuticals Stock Forecast
CTXR's stock price has decreased by -92.44% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Citius Pharmaceuticals stock have an average target of 54.5, with a low estimate of 9.00 and a high estimate of 100. The average target predicts an increase of 3,557.72% from the current stock price of 1.49.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 18, 2025.
Analyst Ratings
The average analyst rating for Citius Pharmaceuticals stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $9 | Strong Buy | Maintains | $9 | +504.03% | Feb 18, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $9 | Strong Buy | Maintains | $9 | +504.03% | Jan 7, 2025 |
| D. Boral Capital | D. Boral Capital | Hold → Strong Buy Upgrades $9 | Hold → Strong Buy | Upgrades | $9 | +504.03% | Dec 30, 2024 |
| D. Boral Capital | D. Boral Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 22, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +6,611.41% | Nov 12, 2024 |
Financial Forecast
Revenue This Year
n/a
from 296.41M
Revenue Next Year
n/a
EPS This Year
-1.88
from -5.97
EPS Next Year
1.38
from -1.88
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 28.0M | 82.2M | 183.8M | ||
| Avg | 14.3M | 69.1M | 162.6M | ||
| Low | n/a | 56.2M | 140.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -90.6% | 475.4% | 165.8% | ||
| Avg | -95.2% | 384.0% | 135.2% | ||
| Low | - | 293.0% | 103.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.35 | 3.94 | 3.61 | ||
| Avg | -1.88 | 1.38 | 2.54 | ||
| Low | -4.41 | -0.91 | 1.52 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 161.0% | ||
| Avg | - | - | 83.9% | ||
| Low | - | - | 9.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.